- Home
- NEN vs ABEO Comparison
NEN vs ABEO Comparison
Compare NEN & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEN
- ABEO
- Stock Information
- Founded
- NEN 1977
- ABEO 1974
- Country
- NEN United States
- ABEO United States
- Employees
- NEN N/A
- ABEO N/A
- Industry
- NEN Building operators
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- NEN Real Estate
- ABEO Health Care
- Exchange
- NEN Nasdaq
- ABEO Nasdaq
- Market Cap
- NEN 277.7M
- ABEO 260.1M
- IPO Year
- NEN N/A
- ABEO 1980
- Fundamental
- Price
- NEN $77.25
- ABEO $5.27
- Analyst Decision
- NEN
- ABEO Strong Buy
- Analyst Count
- NEN 0
- ABEO 5
- Target Price
- NEN N/A
- ABEO $18.00
- AVG Volume (30 Days)
- NEN 592.0
- ABEO 3.0M
- Earning Date
- NEN 01-01-0001
- ABEO 05-19-2025
- Dividend Yield
- NEN 6.21%
- ABEO N/A
- EPS Growth
- NEN 87.60
- ABEO N/A
- EPS
- NEN 4.46
- ABEO N/A
- Revenue
- NEN $81,814,652.00
- ABEO N/A
- Revenue This Year
- NEN N/A
- ABEO N/A
- Revenue Next Year
- NEN N/A
- ABEO $539.93
- P/E Ratio
- NEN $17.32
- ABEO N/A
- Revenue Growth
- NEN 8.57
- ABEO N/A
- 52 Week Low
- NEN $67.50
- ABEO $3.93
- 52 Week High
- NEN $84.00
- ABEO $7.32
- Technical
- Relative Strength Index (RSI)
- NEN 43.89
- ABEO 47.62
- Support Level
- NEN $76.00
- ABEO $5.12
- Resistance Level
- NEN $78.75
- ABEO $7.08
- Average True Range (ATR)
- NEN 0.45
- ABEO 0.58
- MACD
- NEN 0.02
- ABEO -0.04
- Stochastic Oscillator
- NEN 31.17
- ABEO 16.33
About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.